title: Antitumour efficacy of two paclitaxel formulations for hyperthermic intraperitoneal chemotherapy (HIPEC) in an in vivo rat model.
abstract: OBJECTIVE
  To evaluate the tumour growth delay of a peritoneal carcinomatosis (PC) of colorectal origin after intraperitoneal chemotherapy with paclitaxel/randomly-methylated-β-cyclodextrin (Pac/RAME-β-CD) versus Taxol® at normo- and hyperthermic conditions in rats.
  
  
  METHODS
  Hyperthermic intraperitoneal chemotherapy (HIPEC) was performed 7 days post implantation of the tumour with both formulations at a Pac concentration of 0.24 mg/ml. Tumour evaluation was performed via positron emission tomography (PET) and magnetic resonance imaging (MRI) imaging, measuring tumour activity and tumour volume, respectively. Scans were taken at 2 and 7 days post treatment.
  
  
  RESULTS
  PET and MRI data showed a significant reduction in tumour activity and tumour volume for rats treated with Pac/RAME-β-CD (at normo- and hyperthermic conditions), compared to the control group. Treatment with Taxol® did not result in a significant reduction of tumour activity and tumour volume. No significant differences between the normo- and hyperthermic conditions were observed for both formulations, indicating that hyperthermia and paclitaxel were not synergistic despite the direct cytotoxic effect of hyperthermia.
  
  
  CONCLUSIONS
  Monitoring tumour growth via PET and MRI indicated that Pac/RAME-β-CD inclusion complexes had a significantly higher efficacy compared to Taxol® in a rat model for peritoneal carcinomatosis.
authors.affiliation: Laboratory of Pharmaceutical Technology, Ghent University, Harelbekestraat 72, Ghent, 9000, Belgium.
authors.forename: Wim
authors.initials: W
authors.lastname: Bouquet
authors.forename: Steven
authors.initials: S
authors.lastname: Deleye
authors.forename: Steven
authors.initials: S
authors.lastname: Staelens
authors.forename: Lieselotte
authors.initials: L
authors.lastname: De Smet
authors.forename: Nancy
authors.initials: N
authors.lastname: Van Damme
authors.forename: Isabelle
authors.initials: I
authors.lastname: Debergh
authors.forename: Wim P
authors.initials: WP
authors.lastname: Ceelen
authors.forename: Filip
authors.initials: F
authors.lastname: De Vos
authors.forename: Jean Paul
authors.initials: JP
authors.lastname: Remon
authors.forename: Chris
authors.initials: C
authors.lastname: Vervaet
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D003131:Combined Modality Therapy; D004195:Disease Models, Animal; D006979:Hyperthermia, Induced; D007274:Injections, Intraperitoneal; D008279:Magnetic Resonance Imaging; D017239:Paclitaxel / Q000627:therapeutic use*; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000517:prevention & control; D049268:Positron-Emission Tomography; D051381:Rats; D013997:Time Factors; D047368:Tumor Burden; D047392:beta-Cyclodextrins / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D047392:beta-Cyclodextrins; D017239:Paclitaxel